This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, New Zealand, Poland, Singapore, Spain, Turkey, UK.
The drug ANORO ELLIPTA contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
7AN603V4JV - UMECLIDINIUM BROMIDE
|
|
Umeclidinium is a long acting muscarinic receptor antagonist (also referred to as an anticholinergic). It is a quinuclidine derivative that is a muscarinic receptor antagonist with activity across multiple muscarinic cholinergic receptor subtypes. Umeclidinium bromide exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic cholinergic receptors on airway smooth muscle. |
|
2
|
UNII
40AHO2C6DG - VILANTEROL TRIFENATATE
|
|
Vilanterol is a selective long-acting, beta2-adrenergic agonist (LABA). The pharmacologic effects of beta2-adrenoceptor agonist active substances, including vilanterol, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| ANORO ELLIPTA Inhalation powder, pre-dispensed | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| R03AL03 | Vilanterol and umeclidinium bromide | R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AL Adrenergics in combination with anticholinergics |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 10188F |
| BR | Câmara de Regulação do Mercado de Medicamentos | 510616030054502, 510616030054602 |
| CA | Health Products and Food Branch | 02418401 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 546-MEE-1214 |
| EE | Ravimiamet | 1649213, 1649224, 1649235 |
| ES | Centro de información online de medicamentos de la AEMPS | 113898002 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 154976, 162084 |
| FR | Base de données publique des médicaments | 67657035 |
| GB | Medicines & Healthcare Products Regulatory Agency | 246447, 379795 |
| HK | Department of Health Drug Office | 63414 |
| IE | Health Products Regulatory Authority | 13244, 24700 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 7557 |
| JP | 医薬品医療機器総合機構 | 2259806G1021, 2259806G2028 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1073421, 1073422, 1073423 |
| NZ | Medicines and Medical Devices Safety Authority | 15891 |
| PL | Rejestru Produktów Leczniczych | 100313368 |
| SG | Health Sciences Authority | 14838P |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699522557660, 8699522557684 |
| US | FDA, National Drug Code | 0173-0869 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.